William Kilgore, MD
Gastroenterology · Wichita, KSNPI 1295770832
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Janssen Research & Development, LLC at 59.3% of the total. Reporting peaked in 2024 at $3,273 and has fallen 90.4% since, to $315 in 2025.
Across 75 payments — averaging $67.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$3K
- AbbVie$575
- Johnson & Johnson$456
- Lilly USA, LLC$330
- Janssen Scientific Affairs, LLC$125
- E.r. Squibb & Sons, L.L.C.$108
- plus $479 from 12 others
Across 229 payments — averaging $4339.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$623K
- AbbVie$365K
- Janssen Research & Development, LLC$6K
What the payments were for
- Consulting fees$3,02559%
- Food & beverage$1,91538%
- Education$1573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 1 | $3,025 |
| AbbVie | 15 | $575 |
| Johnson & Johnson(2 entities) | 27 | $456 |
| Lilly USA, LLC | 3 | $330 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| Boston Scientific | 6 | $106 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Gilead | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $39 |
| Pfizer | 2 | $35 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Shire North American Group Inc | 2 | $24 |
| CSL Behring | 1 | $16 |
| Bayer | 1 | $14 |
| QOL Medical, LLC | 1 | $12 |
| Edwards Lifesciences | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,097 in reported general payments places this provider in the 75th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 59 | $1,607,763 |
| Humira(Cf) PenAdalimumab | 46 | $313,752 |
| XifaxanRifaximin | 44 | $136,023 |
| Mesalamine | 136 | $51,898 |
| LinzessLinaclotide | 71 | $51,184 |
| CreonLipase/Protease/Amylase | 43 | $47,485 |
| Balsalazide Disodium | 107 | $14,951 |
| MovantikNaloxegol Oxalate | 18 | $13,061 |
| Alosetron Hcl | 17 | $6,678 |
| Mesalamine ErMesalamine | 45 | $6,015 |
| Dexlansoprazole DrDexlansoprazole | 34 | $5,846 |
| Budesonide DrBudesonide | 42 | $5,594 |
| Ursodiol | 80 | $5,593 |
| Tenofovir Disoproxil Fumarate | 16 | $5,127 |
| Mercaptopurine | 38 | $4,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $456 | $1,607,76359 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $28 | $137,85357 claims |
| AbbVieLinzess, Creon | $575 | $98,669114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Wichita
- Mark BowlesWichita$11K
- Estephan ZayatWichita$10K
- Maria ChangWichita$6K
- Winnie Sheu WocWichita$6K
- Obada TayyemWichita$5K
- Saritha GorantlaWichita$3K
- Gebran KhneizerWichita$3K
- Bassem MattaWichita$3K
- Michael LievensWichita$1K
- Natalie FarhaWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.